{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Overall Response is complete remission (CR) + CR with incomplete hematologic recovery (CRi) + Partial remission (PR) + Hematologic improvement (HI) + Morphologic Leukemia-Free State (MLF). (CR) is Bone marrow; \\</=5% blasts, no Auer rods or extramedullary disease and peripheral blood counts \\>/= 1.0x10\\^9/L Neutrophils, \\>/= 100x10\\^9/L platelets and no circulating blasts. (CRi), same as CR for bone marrow and \\<1.0x10\\^9/L neutrophils and \\< 100x10\\^9/L platelets in peripheral blood counts. PR is all CR criteria if abnormal prior to treatment except \\>/= 50%reduction in bone marrow blast but still \\> 5%. MLF is \\</=5% myeloblasts on bone marrow . HI response must be described by the number of positively affected cell lines..","groups":[{"description":"Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nErlotinib Hydrochloride: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (Erlotinib Hydrochloride)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 3 months post-treatment","title":"Participants With a Response","type":"PRIMARY","unitOfMeasure":"Participants"}